Winfried Teiwes, Ph.D.
Co-Founder in 2008 and CEO
Founder and CEO of SMI, redefining refractive and cataract laser surgery with tracking and guidance
OD-OS aims to set new standards of care for retina treatment. By extending our innovative Retina Navigation platform, our goal is to become the global leader in novel therapeutic solutions for the growing number of people suffering from retina diseases.
We are striving to preserve the eyesight of patients with retina disease. Our German-American team of experts in ophthalmic devices works closely with eye doctors, clinical specialists and partners all over the world to advance the treatment of diabetic retinopathy.
We provide innovative therapy solutions, being the first to introduce Retina Navigation with its unique integration of imaging, planning, treatment, and documentation - utilizing our advanced overlay technology.
The name OD-OS was chosen for the company as it is instantly recognizable and easily remembered by anyone who is involved in retina therapy. OD-OS denotes the right eye (Oculus Dexter) and left eye (Oculus Sinister), as is commonly used in everyday documentation by eye doctors. Furthermore, OD-OS also stands for Ophthalmic Diagnostics - Ophthalmic Surgery. And it is this unique combination of the two aspects of standard care that points to the company's goal: OD-OS is breaking new ground in integrating both the diagnosis and therapy in one solution utilizing Retina Navigation. Allowing you to Image, Plan, Treat, and Document with a single device.
OD-OS is an offshoot of SensoMotoric Instruments GmbH (SMI), located in Teltow, just outside of Berlin, Germany. At the start of 2008, after more than three years of product and technological development at SMI by a team dedicated to Retina Navigation, OD-OS was created with a solid capital base and the focused target of bringing Retina Navigation to the market.
OD-OS is an ISO 9001 and ISO 13485 certified medical device company.
To develop innovative therapy solutions with Navilas, OD-OS continues to develop new products and technologies to enhance the treatment of the retina with laser by providing a more quality controlled treatment process, such as better treatment strategies for treatment planning, enhanced treatment evaluation and dosimetry (in the LADOS-Project) and using advanced imaging technologies (in the OCT-Navigation-Project). The projects mentioned before were funded by the Ministry of Economic Affairs of Brandenburg and the EU.